Pre-exposure prophylaxis for HIV transmission? No, unless

Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) will soon be available in the Netherlands. Moderate evidence concerning practical efficacy, small absolute risk reduction (1-2%) and a high number needed to treat (50-75) are key figures. Prevention of one HIV infection will cost...

Full description

Saved in:

Bibliographic Details
Published in:	Nederlands tijdschrift voor geneeskunde Vol. 157; no. 27; p. A6359
Main Authors:	Boeke, A J P Joan, Heijnen, Adrie M
Format:	Journal Article
Language:	Dutch
Published:	Netherlands 2013
Subjects:	Adenine - administration & dosage Adenine - analogs & derivatives Anti-HIV Agents - administration & dosage Chemoprevention Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Emtricitabine HIV Infections - prevention & control Humans Organophosphonates - administration & dosage Tenofovir
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) will soon be available in the Netherlands. Moderate evidence concerning practical efficacy, small absolute risk reduction (1-2%) and a high number needed to treat (50-75) are key figures. Prevention of one HIV infection will cost EUR 350,000 to 500,000. No information is available on long-term renal function and antiretroviral resistance. Guidelines are needed before treatment with PrEP is introduced in the Netherlands.
ISSN:	0028-2162 1876-8784